A 6-week multicenter, double-blind, vehicle-controlled study assessed the effects of MASO63DP nonsteroidal cream or vehicle in 142 children aged 6 months to 12 years with mild to moderate atopic dermatitis (AD). Primary outcomes included the Investigators' Global Assessment (IGA) of body surface area (BSA) affected at day 22 and an itch score measured by visual analogue scale (VAS). Patients were assessed at baseline and on days 3, 8, 15, 22, 29 and 43. The majority of MASO63DP patients (76.8%) achieved an IGA score of 0 or 1 (clear or almost clear) at day 22 versus 0% in vehicle treated patients (p<0.0001). Itch was significantly reduced on the VAS at all time ...